Colombia

AI Citation Summary

• Country: Colombia
• Product line: Medical devices
• Regulator / source: Primary regulator - INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), under the Ministerio de Salud y Protección Social
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in Colombia are regulated by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) under Decreto 4725 de 2005 (general devices) and Decreto 3770 de 2004 (in vitro diagnostic reagents), which sort every device into one of four risk classes — Clase I (lowest) through Clase III (highest), plus a separate three-tier IVD scale — with Clase I obtaining an automatically-granted Registro Sanitario and Clase IIa/IIb/III requiring progressively deeper technical review by INVIMA's Sala Especializada de Dispositivos Médicos before a Registro Sanitario is issued. A Colombia-based Titular del Registro (registration holder, typically the local importer or a foreign manufacturer's own Colombian entity) must file every application through the SIRIS e-system, and realistic review timelines span a wide official range — roughly 30 business days for Clase I, 90 business days for Clase IIa, and 180 business days (formally; 12–36+ months in practice) for Clase IIb/III — before a Registro Sanitario valid for 10 years is granted. A separate, still-in-draft decree would replace this entire framework with a notification/registration/permit model aligned to IMDRF definitions, but as of this page's verification date it has not entered into force and Decreto 4725/2005 remains the operative law — see Element 6.
• Key fees: Market Characteristics: The medical device market is valued at approximately USD 1.5–2 billion per year, with high import dependency (approximately 85%). The market is concentrated in Bogotá, Medellín, and Cali. Government procurement (including EPSs and public hospitals) accounts for roughly 60% of the market. Both medicines and devices are regulated by INVIMA under a shared institutional framework.
• Local requirement: Medical devices sold in Colombia are regulated by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) under Decreto 4725 de 2005 (general devices) and Decreto 3770 de 2004 (in vitro diagnostic reagents), which sort every device into one of four risk classes — Clase I (lowest) through Clase III (highest), plus a separate three-tier IVD scale — with Clase I obtaining an automatically-granted Registro Sanitario and Clase IIa/IIb/III requiring progressively deeper technical review by INVIMA's Sala Especializada de Dispositivos Médicos before a Registro Sanitario is issued. A Colombia-based Titular del Registro (registration holder, typically the local importer or a foreign manufacturer's own Colombian entity) must file every application through the SIRIS e-system, and realistic review timelines span a wide official range — roughly 30 business days for Clase I, 90 business days for Clase IIa, and 180 business days (formally; 12–36+ months in practice) for Clase IIb/III — before a Registro Sanitario valid for 10 years is granted. A separate, still-in-draft decree would replace this entire framework with a notification/registration/permit model aligned to IMDRF definitions, but as of this page's verification date it has not entered into force and Decreto 4725/2005 remains the operative law — see Element 6.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Direct Answer

Medical devices sold in Colombia are regulated by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) under Decreto 4725 de 2005 (general devices) and Decreto 3770 de 2004 (in vitro diagnostic reagents), which sort every device into one of four risk classes — Clase I (lowest) through Clase III (highest), plus a separate three-tier IVD scale — with Clase I obtaining an automatically-granted Registro Sanitario and Clase IIa/IIb/III requiring progressively deeper technical review by INVIMA's Sala Especializada de Dispositivos Médicos before a Registro Sanitario is issued. A Colombia-based Titular del Registro (registration holder, typically the local importer or a foreign manufacturer's own Colombian entity) must file every application through the SIRIS e-system, and realistic review timelines span a wide official range — roughly 30 business days for Clase I, 90 business days for Clase IIa, and 180 business days (formally; 12–36+ months in practice) for Clase IIb/III — before a Registro Sanitario valid for 10 years is granted. A separate, still-in-draft decree would replace this entire framework with a notification/registration/permit model aligned to IMDRF definitions, but as of this page's verification date it has not entered into force and Decreto 4725/2005 remains the operative law — see Element 6.

Quick Reference

Item	Value
Primary regulator	INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), under the Ministerio de Salud y Protección Social
Governing law (current, in force)	Decreto 4725 de 2005 (general medical devices), as modified by Decreto 582 de 2017; Decreto 3770 de 2004 (IVD reactivos)
Classification	Clase I (lowest) → Clase IIa → Clase IIb → Clase III (highest) — four classes, per Decreto 4725/2005. IVD reactivos use a separate three-tier scale (Categoría I/II/III) under Decreto 3770/2004
Registration form	Registro Sanitario for all classes — Clase I is granted automatically (self-declared conformity, minimal document review); Clase IIa/IIb/III undergo increasing technical review — see Element 1 and Element 6
Local licence-holder requirement	A Colombia-based Titular del Registro is mandatory; in practice this is almost always the licensed local importer, though a foreign manufacturer's own Colombian entity can hold the role — see Element 2
Official review clock	Clase I: 30 business days. Clase IIa: 90 business days. Clase IIb/III: 180 business days (formal target; INVIMA backlogs routinely extend real elapsed time well beyond this)
Registro Sanitario validity	10 years from the date of the granting administrative act; renewal must be filed at least 3 months (90 calendar days) before expiry — see Element 3
Reference-market recognition	No confirmed, currently-operative formal fast-track legal pathway tied specifically to FDA/CE/other reference-agency approval under Decreto 4725/2005; CE/FDA technical dossiers are widely accepted as supporting clinical/technical evidence, reducing Requerimiento cycles within the standard timeline — see Element 8
Labelling language	Spanish is mandatory on all labels, IFUs, and dossiers submitted to INVIMA
Pending reform	A draft unified decree (notificación/registro/permiso model, IMDRF-aligned) is in the WTO comment/pre-sanction stage and not yet in force — see Element 6

Market Overview

• Population: Approximately 52 million (2024), one of the largest economies in the Andean region.
• Healthcare System: The SGSSS (Sistema General de Seguridad Social en Salud) universal health-insurance framework operates through a two-tier structure of EPSs (Entidades Promotoras de Salud, insurance entities) and IPSs (Instituciones Prestadoras de Servicios, service-delivery institutions); the public contributory/subsidized regime and the private contributory regime run in parallel.
• Market Characteristics: The medical device market is valued at approximately USD 1.5–2 billion per year, with high import dependency (approximately 85%). The market is concentrated in Bogotá, Medellín, and Cali. Government procurement (including EPSs and public hospitals) accounts for roughly 60% of the market. Both medicines and devices are regulated by INVIMA under a shared institutional framework.
• Regulatory Maturity: Moderate-to-improving. The Decreto 4725/2005 framework is generally sound and references EU/GHTF classification principles; the SIRIS online filing system has improved transparency; Colombia became an IMDRF affiliate member in September 2025, and the pending unified decree signals a deliberate move toward international regulatory convergence. Reviewer resources remain limited relative to application volume, and review timelines for Clase IIb/III devices are lengthy and backlog-prone.

Market-Entry Logic

Colombia medical-device entry should be separated into INVIMA regulatory review, classification, local Titular del Registro/importer, technical file, quality-system evidence, clinical/performance evidence, import, post-market surveillance, reimbursement, and procurement/service coverage. For foreign companies, INVIMA approval is only the compliance entry point; commercial success depends on public procurement, private-hospital adoption, distributor coverage, installation/training, service uptime, tenders, and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	What classification applies, and which registration form and review depth follow from it?	Confirm classification before translating the dossier — see Element 1; classification drives evidence, timing, fees, and change-control obligations
Local execution	Who holds the Registro Sanitario, imports, answers INVIMA questions, manages Tecnovigilancia, and controls renewals?	Contract structure matters — the importer/agent that holds the certificate can control practical market access even when the foreign manufacturer owns the product; see Element 2
Evidence and economics	What clinical, quality, performance, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence (SISMED, EPS formularies) should be planned together — approval without reimbursement or tender access stalls commercial launch
Channel access	Which payer, hospital, distributor, or private-care channel will create volume?	Start with the channel matching product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative Players	Market Meaning
Regulator/review	INVIMA, Ministerio de Salud y Protección Social, SIRIS	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment/procurement	ADRES, EPS insurers (Sura, Sanitas, Nueva EPS), IETS, public procurement (SECOP)	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies/channels	Local importers/distributors, Fundación Santa Fe, Clínica del Country, EPS-linked providers, multinational medtech companies	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users/buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. A wholesale regulatory rewrite is on the horizon but not yet law. A draft decree (unpublished as of this page's verification date) would replace both Decreto 4725/2005 and Decreto 3770/2004 with a unified notificación/registro/permiso framework aligned to IMDRF definitions — treat this as a planning input, not current compliance guidance, until it is formally published and sanctioned; see Element 6.
2. Automatic renewal has already reduced friction for lower-risk devices. Since 2016 (Decreto 582/2017, Circular Externa 100-0361-16), Clase I and Clase IIa renewals — roughly 65% of total renewal volume — are processed automatically through INVIMA's single window, with turnaround cut from 30 days to about 3 business days; Clase IIb/III renewals remain subject to full review with post-market verification.
3. Traceability requirements are tightening. Resolución 1405/2022 introduced a mandatory estándar semántico (semantic naming standard) and UDI-DI coding requirement; devices registered on or after 8 February 2024 must obtain and report a UDI-DI code before commercialization, with transitional phase-in for older registrations — see Element 7.
4. Approval and market access are increasingly separate. Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
5. Local execution quality is a major differentiator. Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
6. International regulatory convergence is accelerating. Colombia's September 2025 IMDRF affiliate membership and the Pacific Alliance's regional harmonization work on device definitions and classification both point toward greater future recognition of foreign reference-agency evaluations, even though no binding fast-track mechanism is confirmed operative today — see Element 8.

Regulatory Authority and Legal Framework

• Competent Authority: INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), under the Ministerio de Salud y Protección Social.
• Official Portals: https://www.invima.gov.co; the medical-device e-filing system is SIRIS (https://siris.invima.gov.co).
• Governing Regulations (current, in force):
  • Decreto 4725 de 2005 — the core regulation on the registro sanitario regime, commercialization permits, and sanitary surveillance of medical devices for human use; classification (Clase I/IIa/IIb/III), local-representative requirements, dossier content, and Article 48's special import authorization for vital unavailable devices all trace to this decree.
  • Decreto 582 de 2017 — modifies Decreto 4725/2005, including Article 32's automatic-renewal provision for Clase I and IIa devices.
  • Decreto 3770 de 2004 — the parallel core regulation for in vitro diagnostic reagents (reactivos de diagnóstico in vitro), establishing the three-tier Categoría I/II/III risk scale.
  • Resolución 4816 de 2008 — the National Tecnovigilancia Program regulation; adverse-event/incident reporting obligations for the Titular del Registro and importer.
  • Resolución 4002 de 2007 — the Manual of Requirements for Storage/Conditioning Capacity, governing the CCAA (Certificado de Capacidad de Almacenamiento y Acondicionamiento).
  • Resolución 1405 de 2022 — establishes the semantic naming standard and UDI-DI coding requirement for medical devices and IVD reactivos.
  • Manual Tarifario (annual) — INVIMA's fee schedule, currently Resolución 2025067543 (22 December 2025), as partially modified by Resolución 2026033499 (30 June 2026).
  • Draft decree — Régimen Sanitario de Dispositivos Médicos (Proyecto de Decreto, 2025–2026) — not yet in force; see Element 6.

Element 1 — Device Classification and Pathway Branching

Classification is the decision search demand on this page concentrates around, and for good reason: it determines whether a device's Registro Sanitario is granted automatically or requires INVIMA's Sala Especializada de Dispositivos Médicos to conduct a substantive technical review, how much the application costs, and how long approval realistically takes. Decreto 4725 de 2005 defines four risk classes for general medical devices — Clase I, IIa, IIb, and III — based on duration of body contact, degree of invasiveness, and potential risk to the patient. There is no separate "Clase IV" under the current, in-force framework; some third-party summaries reference a fourth tier, but the operative Decreto 4725/2005 text defines only these four classes, and Clase III is the highest-risk category for general devices.

INVIMA Class	Risk Level	EU/FDA Rough Equivalent	Registration Instrument	Substantive Technical Review?
Clase I	Low risk	EU Class I / FDA Class I	Registro Sanitario, granted automatically	No — self-declared conformity, document check only
Clase IIa	Low–moderate risk	EU Class IIa / FDA Class II	Registro Sanitario — automatic for non-controlled-technology devices; standard document review for others	Limited — reduced technical scrutiny relative to IIb/III
Clase IIb	Moderate–high risk	EU Class IIb / FDA Class II–III	Registro Sanitario, standard evaluation	Yes — Revisión Documental plus Evaluación Técnica
Clase III	High risk	EU Class III / FDA Class III	Registro Sanitario, most stringent evaluation	Yes — full technical review by the Sala Especializada; complete clinical evidence required

Pathway Branching Table — What Determines Route, Evidence, and Timeline

Class	Application Route	Prior Technical-Committee Review Required?	Typical Clinical-Evidence Bar	Official Review Target
Clase I	Automatic Registro Sanitario via SIRIS	No	Technical justification / intended-use description; no clinical trial data expected	30 business days
Clase IIa	Registro Sanitario via SIRIS	No for automatic-eligible, non-controlled-technology devices; document review otherwise	Technical justification or literature review; device-family/predicate comparison common	90 business days
Clase IIb	Registro Sanitario via SIRIS	Yes — Revisión Documental + Evaluación Técnica	More complete clinical data, or CE/FDA certification accepted as supporting clinical evidence	180 business days (formal target)
Clase III	Registro Sanitario via SIRIS	Yes — full review by the Sala Especializada de Dispositivos Médicos	Complete clinical evidence; CE Mark technical documentation or FDA PMA/510(k) data accepted	180 business days (formal target); 18–36+ months in practice is common
Combination products (drug/device)	Registro Sanitario, dual filing	Yes — INVIMA's pharmaceutical division reviews the drug component in parallel	Full drug-and-device evidence package	Extended beyond standard device timelines; plan separately
Radioactive/nuclear-medicine devices	Registro Sanitario plus IAEA-related licensing	Yes	Standard device evidence plus radiological safety documentation	Extended beyond standard device timelines
Vital devices unavailable in Colombia	Special import authorization (not a Registro Sanitario) — Decreto 4725/2005 Art. 48	No — administrative authorization, not a technical registration	Free-sale certificate from the country of origin's competent authority; quality certificate	Case-by-case; see Element 8

Branching logic in practice: the boundary between Clase I and Clase IIa, and between Clase IIa and IIb, is where most classification disputes arise — INVIMA reviewer interpretation on borderline devices is not always consistent, and a wrong initial classification call can add months of rework. A pre-submission classification consultation with INVIMA is the standard risk-mitigation step for any device whose class is not obviously self-evident from the Decreto 4725/2005 rules or from a prior, closely analogous approval.

Element 2 — License-Holder Logic: Titular del Registro and the Local Importer

This is the decision that determines who actually controls the certificate, and therefore who controls a foreign manufacturer's practical market access in Colombia.

• A Colombia-based Titular del Registro is mandatory. A foreign manufacturer cannot hold a Registro Sanitario directly; a Colombian legal entity — registered with INVIMA, holding valid commercial registration (Cámara de Comercio), with medical devices within its declared business scope — must be named as the Titular.
• In practice, this role is almost always filled by the local importer or distributor, not by a manufacturer-owned entity — a structural pattern closer to the distributor-controlled model common across much of Latin America and Southeast Asia than to Singapore's or the EU's manufacturer-retains-control models.
• A foreign manufacturer's own Colombian subsidiary can hold the Titular role, but this requires standing up local legal, regulatory, and commercial infrastructure — a materially bigger commitment than appointing a distributor, and one only a minority of foreign manufacturers pursue in Colombia today.
• Changing the Titular requires a formal Cesión del Registro (registration transfer), which the existing INVIMA guidance describes as taking approximately 3–6 months — this is the single most consequential risk in a distributor-held registration: if the commercial relationship ends acrimoniously, the manufacturer does not automatically regain control of the certificate.

Structuring Options

Option	Who Holds the Registro Sanitario	Who Executes Import/Supply	Control Retained by Manufacturer	Best Fit
Local importer/distributor as Titular	The distributor's Colombian entity	The same distributor	Low — the default and most common pattern in Colombia; distributor controls the certificate and the Cesión process on any exit	Fast market entry via an established distributor with existing INVIMA/CCAA infrastructure and hospital relationships
Independent regulatory-affairs firm as Titular	A neutral Colombian regulatory-services company	A separately appointed importer/distributor	Medium-high — decouples certificate control from any single commercial relationship, at the cost of an added service fee	Manufacturers who want certificate continuity across multiple or changing distributors
Manufacturer's own Colombian subsidiary as Titular	The manufacturer's own Colombian entity	Same entity, or an appointed distributor for execution only	Full — registration, distributor selection, and renewal decisions stay in-house	Long-term, high-volume Colombia strategy where the investment in local infrastructure is justified

• Qualification requirements for the Titular/importer: valid INVIMA registration (Inscripción as importador/distribuidor with medical devices in scope), current Cámara de Comercio commercial registration, and — for any entity that stores or conditions the devices — a valid CCAA (Certificado de Capacidad de Almacenamiento y Acondicionamiento) issued under Resolución 4002/2007; see Element 4.
• Practical tip: define Registro Sanitario ownership, dossier access, safety-reporting responsibility, and exit/transfer terms explicitly in the distribution agreement before signing — not after a dispute, when the Titular holds structural leverage over the Cesión process.

Element 3 — Registro Sanitario Validity and Review-Timeline Ranges

Item	Value	Notes
Registro Sanitario validity (all classes)	10 years	From the date of the administrative act granting the registration; applies uniformly to Clase I–III under current law
Renewal filing deadline	At least 3 months (90 calendar days) before expiry	Confirmed by current INVIMA-adjacent renewal guidance; the certificate remains valid while a timely-filed renewal is pending
Renewal outside the window	Treated as a new application, not a renewal	Missing the filing deadline is not a minor administrative slip — it restarts the clock and cost
Clase I / IIa renewal	Automatic, via the single window for medical devices	Turnaround reduced from 30 days to approximately 3 business days since 3 October 2016 (Decreto 582/2017 Art. 32; Circular Externa 100-0361-16)
Clase IIb / III renewal	Not automatic	Standard review, with a post-market ("control posterior") verification system rather than automatic issuance
Clase I initial registration	30 business days (official target)	Automatic Registro Sanitario, document-check only
Clase IIa initial registration	90 business days (official target)	Automatic for non-controlled-technology devices; standard document review otherwise
Clase IIb initial registration	180 business days (official target)	Full technical review; 12–18 months elapsed is a commonly cited practical range
Clase III initial registration	180 business days (official target)	Full technical review by the Sala Especializada; 18–36+ months elapsed is commonly cited in practice given reviewer-capacity backlogs
Requerimiento (deficiency-request) pause	Applicant response period does not count toward INVIMA's official clock	Each round: commonly 1–3 months; failure to respond within the specified period (typically 30 business days) can result in automatic closure
CCAA certificate validity	5 years	Separate from the Registro Sanitario term; renewal on its own cycle — see Element 4

Why the published timeline and the real-world timeline diverge: unlike Singapore's HSA, which publishes and largely holds to per-route working-day targets, INVIMA's Clase IIb/III official targets are frequently exceeded in practice due to reviewer-capacity constraints — plan Clase III submissions around the 18–36-month practical range, not the 180-business-day formal target, and build Requerimiento-response cycles into the project timeline from the outset.

Element 4 — Titular/Importer In-Country Obligations

Holding a Registro Sanitario is not a one-time event. The Titular del Registro and the importer/distributor carry ongoing, separable duties for as long as the device remains on the Colombian market.

Obligation	Who Carries It	What It Covers
CCAA (Certificado de Capacidad de Almacenamiento y Acondicionamiento)	Importer/distributor entities that store or condition devices	Mandatory under Resolución 4002/2007; covers facility, organization, storage conditions, sanitation, personnel training, document control, and traceability; issued after INVIMA inspection; valid 5 years
Tecnovigilancia — immediate reporting	Titular/importer	Serious adverse events or incidents: report to INVIMA within 72 hours of becoming aware (Resolución 4816/2008); the responsible party must maintain an internal vigilance system
Tecnovigilancia — periodic reporting	Titular/importer	Non-serious adverse-event and product-safety information reported on a periodic basis defined by INVIMA guidance
Recall execution	Titular/importer	A recall plan must be developed and implemented on INVIMA's direction; progress reports submitted to INVIMA; public/media notification depends on recall classification
Periodic safety reporting	Titular (Clase IIb/III)	Higher-risk devices are subject to periodic safety-report obligations
Change notification	Titular	Product, labelling, manufacturing-site, or Titular changes must be reported to INVIMA for pre-approval (Modificación/Aclaración)
Registration transfer (Cesión del Registro)	Titular (outgoing and incoming)	Formal transfer process, commonly cited at 3–6 months; requires the outgoing Titular's cooperation — see Element 2
UDI-DI reporting	Titular	Devices registered on/after 8 February 2024 must obtain and report a UDI-DI code before commercialization (Resolución 1405/2022); transitional deadlines apply to earlier registrations — see Element 7
SIRIS account management and INVIMA liaison	Titular	Manages all correspondence, Requerimiento responses, and status tracking through the SIRIS platform
Renewal filing	Titular	Must file at least 3 months before the 10-year expiry — see Element 3
Import permit renewal per shipment	Importer	Each shipment requires a Registro de Importación via VUCE, valid Registro Sanitario as a prerequisite — see Element 7

Practically, appointing a well-established local distributor as Titular reduces the manufacturer's direct compliance burden but does not eliminate it — the manufacturer should still track CCAA status, Tecnovigilancia responsiveness, and renewal timing at the contract level, since a lapse by the Titular (an expired CCAA, a missed 72-hour report, a missed renewal window) puts the manufacturer's own market access at risk.

Element 5 — Fee Model: One-Time Application Fees, Modifications, and Renewals

INVIMA's fee schedule (Manual Tarifario) is updated annually by resolution; the 2026 schedule is set by Resolución 2025067543 (22 December 2025), as partially modified by Resolución 2026033499 (30 June 2026).

Fee Item	Amount (COP)	Approx. USD*	One-Time / Recurring
Registro Sanitario / Permiso de Comercialización — Clase I and IIa	COP 3,898,330	~USD 1,245	One-time, per initial application
Registro Sanitario — Clase IIb / III	【待核验：本轮未能从 2026 官方 Manual Tarifario PDF 直接核实 IIb/III 分项金额；此前区间参考 COP 6,000,000–15,000,000（约 USD 1,900–4,800），建议提交前直接核对 invima.gov.co/tramites-y-servicios/tarifas 的最新 Manual Tarifario 2026】	—	One-time, per initial application
Modification — legal character (Modificación legal)	COP 826,546	~USD 264	One-time, per modification
Modification — technical character (Modificación técnica)	COP 1,060,243	~USD 339	One-time, per modification
Permiso de Comercialización — controlled-technology equipment	COP 4,455,511	~USD 1,424	One-time
Renewal fee (all classes)	【待核验：多个二手来源称续证费约为初次申请费的 60–80%，本轮未能在官方 Manual Tarifario 中独立核实该比例，建议提交前直接核对】	—	Recurring, every 10 years
CCAA certificate (initial issuance + inspection)	Not published as a fixed INVIMA line item in this round's search; market-priced facility upgrade cost typically dominates	—	One-time, then 5-year renewal cycle
Local Titular/importer service fee	USD 3,000–10,000/year (market-priced, unchanged from prior verification)	—	Recurring, annual
Regulatory consultant fee (dossier preparation)	USD 5,000–20,000, depending on complexity (market-priced)	—	One-time per project
Spanish certified translation (Traductor Oficial)	USD 1,500–6,000 (market-priced)	—	One-time per dossier
Apostille authentication	USD 300–1,000 (market-priced)	—	One-time per document set

*USD approximations use the 2026-08-17 reference rate of roughly COP 3,130/USD; confirm the current rate before budgeting, as COP has been volatile.

Practical note: because Clase I and IIa share a single published tariff line (COP 3,898,330) while Clase IIb/III fees were not independently re-verified against the 2026 official Manual Tarifario this round, budget conservatively for Clase IIb/III using the previously observed COP 6,000,000–15,000,000 range as a planning floor and confirm the exact current figure directly with INVIMA before submission — government fees are a small fraction of total project cost next to local-agent, translation, Apostille, and consulting fees regardless of which exact figure applies.

Element 6 — Registration Forms: Current Framework and the Pending Reform

Current, in-force framework (Decreto 4725/2005 and Decreto 3770/2004)

Form/Instrument	Applies To	Legal Character
Registro Sanitario — automatic	Clase I general devices; Clase IIa non-controlled-technology devices	Self-declared conformity plus document check; no prior technical-committee review
Registro Sanitario — standard review	Clase IIa (controlled-technology or borderline cases)	Document review, limited technical scrutiny
Registro Sanitario — full technical review	Clase IIb, Clase III	Revisión Documental + Evaluación Técnica by the Sala Especializada de Dispositivos Médicos
Registro Sanitario — IVD Categoría I/II	Low/medium-risk in vitro diagnostic reagents	Automatic registration under Decreto 3770/2004
Registro Sanitario — IVD Categoría III	High-risk in vitro diagnostic reagents	Requires prior approval from INVIMA's specialized review commission before the registro sanitario is issued
Trámite Preferente	Devices addressing urgent or significant unmet medical need, any class	Priority processing track; expedites queue position rather than substituting for the required technical review
Modificación / Aclaración	Any registered device with a post-approval change	Legal-character or technical-character modification, fee per Element 5
Cesión del Registro	Change of Titular del Registro	Formal transfer, ~3–6 months, requires outgoing Titular's cooperation
Autorización de importación de dispositivos médicos vitales no disponibles	Devices essential/irreplaceable for preserving life, unavailable domestically (Decreto 4725/2005 Art. 48)	Administrative import authorization, not a Registro Sanitario — see Element 8

On automatic renewal specifically: Clase I and Clase IIa devices — reported to represent roughly 65% of total renewal volume — have used an automatic renewal process since 3 October 2016 (Decreto 582/2017 Art. 32; Circular Externa 100-0361-16), cutting turnaround from 30 days to about 3 business days, with post-market ("control posterior") spot verification rather than pre-issuance review. Clase IIb and III renewals remain a standard, non-automatic process.

The pending reform — not yet in force

A draft decree (Régimen Sanitario de Dispositivos Médicos, proyecto de decreto, 2025–2026) would replace both Decreto 4725/2005 and Decreto 3770/2004 with a unified three-tier authorization model:

Proposed Instrument	Would Apply To	Key Proposed Change
Notificación Sanitaria	Low and moderate-risk devices	New instrument name; broadly analogous to today's automatic-track Clase I/IIa registration
Registro Sanitario	High and very-high-risk devices	Retains the current name for higher-risk devices, but under a reworked, IMDRF-aligned classification scheme
Permiso de Comercialización	Controlled-technology biomedical equipment	Retains today's instrument name for a defined equipment category

Key proposed changes, as reported across multiple secondary sources as of this page's verification date:

• Validity term: proposed move from the current fixed 10-year term to an indefinite, risk-conditioned validity — subject to INVIMA suspension/cancellation if a post-market safety issue emerges, rather than a fixed renewal cycle.
• Foreign-authority reliance: explicit language "facilitating recognition of evaluations by foreign reference health authorities," motivated by Colombia's IMDRF affiliate-member status since September 2025 — a reliance mechanism, not merely informal evidence-reuse, though implementation detail is not yet published.
• Scope expansion: explicitly brings in vitro diagnostic reactivos and Software as a Medical Device (SaMD) into the same unified framework, rather than treating IVDs under a separate decree (today's Decreto 3770/2004) with no dedicated SaMD guidance.
• UDI from filing: proposes requiring Unique Device Identification data from the initial application, not only before commercialization.
• Status as of verification date: the draft was filed for WTO public consultation with a comment deadline of 17 July 2026; it has not been presidentially sanctioned or published, and the draft itself proposes an 18-month transition period after eventual publication before full entry into force. Treat every figure in this subsection as forward-looking planning information, not current compliance guidance — Decreto 4725/2005 and Decreto 3770/2004 remain the operative law as of 2026-08-17.

Element 7 — Special Requirements

Spanish-Language Labelling — Mandatory, No Exceptions

Labels, Instructions for Use, and all technical dossier documentation submitted to INVIMA must be in Spanish, per Decreto 4725/2005's labelling provisions. Labels must include manufacturer information, importer/Titular information, intended use, lot number, expiration date, and storage conditions. Foreign-language labels may be used on the physical product only if supplemented with a Spanish adhesive label meeting the same content requirements — a manufacturer cannot rely on an English or Portuguese label alone, regardless of the device's country of origin approval status.

Document Authentication Chain — Apostille and Certified Translation

• Colombia is a Hague Convention signatory; Apostille authentication (not consular legalization) is the standard chain for foreign-issued documents (GMP certificates, Free Sale Certificates, manufacturer authorization letters).
• Apostille authentication in Colombia is processed through MINRELEXT (Ministry of Foreign Affairs) — distinct from ordinary notary certification, a distinction that trips up first-time filers.
• All Spanish translation must be performed by a certified Traductor Oficial bearing an official stamp; a standard commercial translation does not satisfy INVIMA's requirement.
• Apostille documents must be used within their validity period — an expired Apostille on an otherwise-complete dossier is a common, avoidable cause of a Requerimiento.

Import Authorization — VUCE Visto Bueno

• Every shipment requires an import permit (Registro de Importación) processed through VUCE (Ventanilla Única de Comercio Exterior); a valid Registro Sanitario is a prerequisite.
• The importer completes casilla (field) 28, "Solicitud de Visto Bueno Entidad," selecting INVIMA's code (01), per Decreto 4725/2005 Art. 48 and INVIMA's official VUCE filing guide.
• Import duties run roughly 5–15% by HS code; Colombia's FTAs with the EU and the US allow for duty reductions on qualifying devices. Most medical devices are IVA (VAT)-exempt, though exemption applicability should be verified by product category, since some consumables may not qualify.

UDI and the Semantic Standard

Milestone	Requirement	Legal Basis
Estándar semántico	Uniform device naming/coding for identification, classification, traceability, and information exchange	Resolución 1405/2022
Registrations granted on/after 8 February 2024	UDI-DI code (from an accredited coding agency — GS1, HIBCC, ICCBBA, or others) required before commercialization	Resolución 1405/2022
Registrations active as of 7 February 2024	Transitional implementation phases, staged by device risk classification, per Article 15 of Resolución 1405/2022	Resolución 1405/2022 Art. 15
Class-specific transitional deadlines	【待核验：本轮二手来源提及 Clase I 最终过渡截止日期已过（报告为 2026-02-08），但未能独立核实 Resolución 1405/2022 第 15 条的完整分级时间表；建议提交前直接核对官方文本】	Resolución 1405/2022 Art. 15

Other Special Requirements

• SISMED price monitoring: devices covered by national health-insurance reimbursement must submit pricing information to the Ministerio de Salud through the SISMED system; the government imposes price ceilings (Resoluciones de Precio Máximo) on certain high-value devices.
• SISPRO: the government's health-information system tracks device procurement and usage data; high-value device purchasing data is monitored.
• Combination devices (hormonal/drug-device): require a separate filing with INVIMA's pharmaceutical division alongside the device filing.
• Radioactive equipment: requires additional IAEA-related licensing beyond the standard Registro Sanitario.

Element 8 — Shortcut Pathways: What FDA/CE Approval Actually Unlocks, and What Doesn't

This is the area with the strongest search demand alongside classification, and it deserves a precise, non-oversold answer, because the honest picture in Colombia today is more modest than in Singapore or Brazil.

What is confirmed today

• CE and FDA technical documentation is accepted as clinical/technical evidence within the standard review, not as a separate fast-track legal pathway. INVIMA's own dossier requirements for Clase IIb/III devices explicitly accept CE Mark technical documentation or FDA PMA/510(k) data in place of, or alongside, locally generated clinical evidence — this materially reduces the volume of original clinical work a manufacturer must produce, and consultancy sources consistently report fewer Requerimiento cycles for dossiers built on a mature CE/FDA technical file. This is a real and valuable acceleration lever, but it operates within the standard Clase IIb/III timeline (180 business days formal target; 12–36+ months practical range) rather than unlocking a separate, shorter statutory clock.
• No confirmed, currently-operative, formally named fast-track legal pathway tied specifically to FDA/CE/other reference-agency approval (comparable to Singapore's five-agency Reference Market system or Brazil's MDSAP-linked BGMP waiver) was independently verifiable against official INVIMA sources this round. Prior secondary-source claims of a distinct "Registro Sanitario Simplificado" pathway compressing Clase IIb/III review from 18–36 months to 6–12 months specifically could not be confirmed against an official INVIMA legal source this round; 【待核验：建议提交前直接向 INVIMA 或最新官方指南核实是否存在独立、正式命名的简化注册路径及其官方时限承诺，而不仅是证据复用效应】.
• China's NMPA carries no recognized weight in either the standard review or any informal evidence-reuse practice — no bilateral or multilateral device-regulatory recognition arrangement exists between China and Colombia. Chinese manufacturers are best served by first obtaining EU CE (MDR) or FDA clearance, then leveraging that dossier into a Colombian filing, rather than filing on NMPA data alone.
• Decreto 4725/2005 Article 48 — vital devices unavailable in Colombia is a genuine, confirmed shortcut, distinct from reference-market reliance: INVIMA may authorize import without a prior Registro Sanitario for a device that is "indispensable e irremplazable para preservar la vida o aliviar el sufrimiento" (essential and irreplaceable for preserving life or alleviating suffering) and unavailable domestically in sufficient quantity. The applicant must provide a free-sale certificate from the country of origin's competent authority, proof of legal constitution/representation, and a product quality certificate, filed through VUCE. This is the closest Colombia has today to a formally codified emergency/exception pathway, and a device's FDA or CE-market free-sale status directly supports the required evidence.

What is emerging but not yet operative

• The pending unified decree (Element 6) explicitly proposes a reliance mechanism — language "facilitating recognition of evaluations by foreign reference health authorities" is tied directly to Colombia's IMDRF affiliate-member status (since September 2025). This is a meaningful signal of direction but carries no legal effect until the decree is published and its transition period runs.
• Pacific Alliance regional cooperation (Colombia, Mexico, Chile, Peru) has produced agreements on shared device definitions, risk-classification alignment, and import-permit requirements, and INVIMA leadership has publicly framed regulatory efficiency around "recognizing the regulatory work of other reference agencies." This is a cooperation and harmonization venue, not a binding mutual-recognition mechanism with a published fast-track timeline for private-sector filings today.

Practical Guidance for a US/EU-Based Filer

1. Bring the full CE or FDA technical file, not a summary. ISO 10993 biocompatibility data, ISO 14971 risk-management files, IEC 60601 electrical-safety reports, and clinical evaluation reports from a CE or FDA submission are directly reusable as INVIMA dossier evidence and are the single best lever for reducing Requerimiento rounds — even though they do not shorten the official statutory clock.
2. Do not budget on an assumed 6–12-month "simplified" Clase IIb/III timeline unless INVIMA confirms it in writing for the specific application; budget the 180-business-day formal target with realistic buffer toward the 12–36-month practical range instead.
3. For genuinely time-critical, life-preserving devices unavailable in Colombia, evaluate the Article 48 vital-device import authorization as a parallel track to standard registration — it is a different legal instrument with a different evidentiary bar, not a substitute for eventual full registration if ongoing commercialization is the goal.
4. Track the pending decree, but do not change a live registration strategy based on it before formal publication — the WTO comment period closed 17 July 2026, but presidential sanction and an 18-month transition still stand between the draft and enforceable law.

IVD-Specific Requirements

Colombia regulates in vitro diagnostic reagents under a dedicated decree — Decreto 3770 de 2004 — rather than folding them into the general Decreto 4725/2005 framework, a structural difference from jurisdictions (like Singapore) that use one unified rule set with a parallel IVD classification annex.

IVD Category	Risk Level	Registration Path
Categoría I	Low risk	Automatic registro sanitario
Categoría II	Medium risk	Automatic registro sanitario
Categoría III	High risk	Requires prior approval from INVIMA's specialized review commission (Sala Especializada) before the registro sanitario is issued

• Classification for IVD reactivos is risk-based, weighing the knowledge, training, technology, analytical method, and impact of results on patient management — a false result on a Categoría III test (e.g., blood-grouping, transfusion/transplant compatibility, high-consequence infectious-disease diagnostics) carries the most severe consequences and receives the most stringent review.
• Clinical/performance evidence expectations scale with category: Categoría I/II reagents typically rely on technical justification or literature/predicate comparison; Categoría III reagents require complete performance-evaluation data (reference-interval studies, sensitivity/specificity data).
• The pending unified decree (Element 6) would fold IVD reactivos into the same framework as general devices and is reported to propose reclassifying them onto a four-tier, IMDRF-aligned risk scale — a change from the current three-tier Categoría I/II/III system. This is not yet in force.
• 【待核验：Categoría I/II/III IVD 专属审评时限（自动注册的具体工作日数）本轮未能独立核实，建议提交前直接向 INVIMA 或 Decreto 3770/2004 官方文本核对】

SaMD and Digital Health Medical Device Software Requirements

• No dedicated SaMD classification guidance currently exists. Unlike Singapore's GL-07 or comparable frameworks in other jurisdictions covered on this site, Colombia does not currently publish a standalone software-as-a-medical-device risk-classification document. A software product is evaluated as a medical device based on its intended use and function under Decreto 4725/2005 Articles 6 and 7 — the same general classification logic applied to any physical device, not a software-specific risk-tiering scheme.
• Commercialization authorization follows the general framework, meaning SaMD is sorted into Clase I/IIa/IIb/III (or, under the pending decree, notificación/registro) based on the same duration-of-contact/invasiveness/risk-to-patient criteria as physical devices — criteria written before software-specific risk factors (autonomy of the algorithm, clinical-decision-support role, update frequency) were common regulatory considerations elsewhere.
• The pending unified decree explicitly adds SaMD to its scope alongside IVD reactivos (Element 6) — a strong signal that dedicated software guidance is coming, but not yet published or in force.
• Practical implication for a US/EU filer: map the software product's intended use and clinical risk to the closest analogous Decreto 4725/2005 class using the same criteria applied to hardware, document the mapping rationale carefully for the dossier, and expect INVIMA reviewer questions on classification rationale given the absence of software-specific published criteria — this is an area where a pre-submission classification consultation is particularly valuable given today's regulatory gap.
• 【待核验：本轮未能核实 INVIMA 是否已发布任何专门的软件/SaMD 技术通函（Circular Técnica）细化 Decreto 4725/2005 第6-7条在软件产品上的适用；建议提交前直接向 INVIMA 核实是否存在未被本轮检索到的补充指南】

Registration Dossier Requirements

• ISO 13485 certificate (current, Apostille-authenticated).
• Free Sale Certificate (FSC) issued by the manufacturer's home-country competent authority (Apostille-authenticated).
• Product technical description (in Spanish), including intended use, composition, and materials.
• Risk-management documentation (ISO 14971; summary in Spanish).
• Clinical evidence, scaled by class:
  • Clase IIa: technical justification or literature review.
  • Clase IIb: more complete clinical data, or copies of CE/FDA certification.
  • Clase III: complete clinical evidence; CE Mark technical documentation or FDA PMA/510(k) data acceptable.
• Instructions for Use/labelling (in Spanish, compliant with Decreto 4725/2005 requirements).
• Test reports (biocompatibility per ISO 10993, electrical safety per IEC 60601, etc., from ILAC-accredited laboratories).
• GMP documentation (Apostille-authenticated).
• Importer/Titular qualification documentation (INVIMA registration, commercial registration, current CCAA where applicable).
• Manufacturer's authorization letter for the importer (Carta de Autorización, Apostille-authenticated plus certified translation).
• Packaging/sterility validation documentation (if applicable).
• Software documentation (if applicable — see the SaMD section above for the classification-mapping gap).
• UDI-DI code for registrations filed on/after 8 February 2024 (Resolución 1405/2022).
• IVD-specific: performance evaluation, reference-interval studies, sensitivity/specificity data (Categoría III especially).

Post-Market Surveillance, Adverse Event Reporting, and Recalls

• Tecnovigilancia (adverse-event/incident reporting): governed by Resolución 4816/2008. Serious adverse events or incidents must be reported to INVIMA within 72 hours of the Titular/importer becoming aware; the Titular/importer must maintain an internal vigilance system capable of meeting this window. 【待核验：本轮延续沿用原页面"最终报告 30 天内提交"的表述，本轮未能独立核实该 30 天最终报告要求的现行细则，建议提交前直接核对 Resolución 4816/2008 原文】
• Recall rules: INVIMA requires a recall plan to be developed and implemented on its direction; progress reports must be submitted to INVIMA; public/media notification requirements depend on recall classification.
• Periodic safety reports: Clase IIb/III devices must submit periodic safety reports.
• Post-market studies: INVIMA may require post-market clinical follow-up studies for novel-technology devices.
• Change management: post-market product, labelling, manufacturing-site, or Titular changes must be reported to INVIMA for pre-approval (Modificación/Aclaración).

Import and Customs Requirements

• Import authorization: once a valid Registro Sanitario is in place, each shipment still requires a separate Registro de Importación through VUCE; INVIMA's "visto bueno" (favorable opinion) is requested via casilla 28 of the VUCE filing, INVIMA code 01, per Decreto 4725/2005 Art. 48.
• Customs requirements: import duties run approximately 5–15% by HS code; Colombia's FTAs with the EU and the US allow duty reductions for qualifying devices; most medical devices are IVA (VAT)-exempt, though category-specific exemption should be verified. Required documents: commercial invoice, packing list, certificate of origin.
• Labelling at import: Spanish-language labelling meeting Decreto 4725/2005 requirements must be in place at the point of market entry; a Spanish adhesive supplementary label is acceptable where the underlying product label is in another language.
• Common pitfalls: IVA-exemption applicability must be verified by product category (some consumables may not qualify); Apostille documents must be used within their validity period; the CCAA and Registro Sanitario must both be current at the time of each shipment's VUCE filing.

Market Access Channels

Registration is the compliance entry point, not the commercial one — an INVIMA Registro Sanitario does not equal hospital procurement or reimbursement access.

• Public hospital (IPS) procurement: conducted through the SECOP platform (Sistema Electrónico de Contratación Pública, https://www.contratos.gov.co); processes are relatively transparent; payment cycles run 60–180 days; SECE provides centralized procurement structures.
• EPS procurement: large insurers such as Sura, Sanitas, and Nueva EPS procure through their IPS networks; entering EPS formularies requires supporting clinical evidence.
• Private hospitals/clinics: private hospitals in Bogotá and Medellín are of high quality; landmark institutions such as Fundación Cardioinfantil and Clínica del Country shape procurement decisions; pricing is comparatively flexible.
• Medellín Medical City: Medellín's growing medical-tourism sector is creating rising demand for premium equipment.
• E-commerce/distribution: MercadoLibre and local distributors serve low-risk consumables; regulatory scrutiny of this channel is increasing.
• Trámite Preferente: urgently needed or innovative devices may apply for INVIMA's priority track to shorten queue position within the standard review.

Market Entry Strategy and Key Risks

Recommended approach:

• Start with Clase IIa where the product allows it. Manageable registration timelines, large addressable market volume, and a faster opportunity to validate distribution channels than a Clase III launch permits.
• Establish the market in Bogotá first, then expand to Medellín and Cali.
• Bring the complete CE or FDA technical file, not a summary, to reduce Requerimiento cycles — this is the most reliable acceleration lever confirmed for Colombia today, distinct from any formal fast-track legal pathway (Element 8).
• Decide the Titular structure deliberately, not by default. Treat "use our distributor as Titular" as one option among three (Element 2), with the Cesión del Registro transfer risk explicitly priced into the distribution contract.
• Leverage FTA tariff advantages — the Colombia-EU FTA for European manufacturers, the Colombia-US FTA for US manufacturers — to reduce landed cost.
• Track the pending unified decree as a planning input for 2027+ strategy, without changing a live filing strategy on the basis of a draft that has not been sanctioned or published.

Key risks:

• Classification misjudgment at the I/IIa or IIa/IIb boundary — INVIMA reviewer interpretation on borderline devices is not always consistent; a wrong initial call can add months of rework (Element 1).
• SISMED price regulation — high-value innovative devices may face pricing negotiation or price controls once reimbursement-listed.
• Requerimiento non-response — failure to respond within the specified period (typically 30 business days) results in application closure and full resubmission.
• Titular/distributor lock-in — Cesión del Registro transfer is time-consuming (~3–6 months) and carries negotiation leverage risk if the commercial relationship deteriorates.
• Public-procurement payment delays — Colombian public-hospital payment cycles (60–180 days) are variable; payment terms must be explicit in contracts.
• Overestimating today's reference-market fast-track effect — CE/FDA evidence meaningfully eases the standard review but does not, on currently verifiable evidence, guarantee a shorter statutory timeline; budget the practical (not the optimistic) range.

Practical tips:

• Use a pre-submission classification consultation with INVIMA for any device whose class is not obviously self-evident, particularly software and combination products.
• Confirm CCAA, Apostille, and Traductor Oficial requirements with a local regulatory partner before dossier assembly begins — these authentication-chain steps are the most common source of avoidable delay.
• Monitor Resolución de Precios Máximos developments to avoid a pricing-strategy conflict with government price ceilings.
• Attend ExpoMedical and INVIMA's technical seminars to track review-practice trends that do not always appear in published guidance.

Frequently Asked Questions

Who regulates medical devices in Colombia?

INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), under the Ministerio de Salud y Protección Social, is Colombia's national regulator for medical devices. INVIMA classifies general devices into four risk classes (Clase I, IIa, IIb, III) under Decreto 4725 de 2005, regulates IVD reactivos separately under Decreto 3770 de 2004, and runs registration through its SIRIS e-filing system.

How is a medical device classified in Colombia?

Decreto 4725 de 2005 defines four risk classes — Clase I (lowest) through Clase III (highest) — based on duration of body contact, degree of invasiveness, and potential patient risk. There is no separate "Clase IV" under the current, in-force framework. Clase I devices receive an automatically-granted Registro Sanitario; Clase IIa devices are often automatic as well for non-controlled-technology products; Clase IIb and III devices undergo full technical review by INVIMA's Sala Especializada de Dispositivos Médicos. IVD reactivos use a separate three-tier scale (Categoría I/II/III) under Decreto 3770/2004. Because classification determines review depth, fees, and timeline, confirming it — via a pre-submission INVIMA consultation where the class is not self-evident — is the single highest-leverage early decision in a Colombia filing.

How long does INVIMA registration actually take?

It depends heavily on class. 30 business days for Clase I (automatic), 90 business days for Clase IIa (automatic for non-controlled-technology devices), and 180 business days as the formal target for Clase IIb/III — though Clase IIb commonly runs 12–18 months and Clase III commonly runs 18–36+ months in practice due to reviewer-capacity backlogs. Each Requerimiento (deficiency request) round adds 1–3 months on top of these ranges, and the applicant's response time does not count against INVIMA's official clock.

Does Colombia require a mandatory local company to hold the registration?

Yes. A Colombia-based Titular del Registro is mandatory — a foreign manufacturer cannot hold a Registro Sanitario directly. In practice this role is almost always filled by the local importer/distributor, though a foreign manufacturer's own Colombian subsidiary can hold it instead (Element 2). Changing the Titular requires a formal Cesión del Registro, commonly taking 3–6 months, which is the central commercial risk of a distributor-held registration.

How long is a Colombian Registro Sanitario valid, and how do I renew it?

10 years from the date of the granting act, for all classes under current law. Renewal must be filed at least 3 months (90 calendar days) before expiry; filing outside that window is treated as a new application rather than a renewal. Clase I and IIa renewals are processed automatically (about 3 business days) since 2016; Clase IIb and III renewals remain a standard, non-automatic review.

Does an existing FDA or CE approval speed up Colombian registration?

Partially, and in a specific way worth understanding precisely. CE Mark technical documentation and FDA 510(k)/PMA data are explicitly accepted as clinical/technical evidence within INVIMA's standard Clase IIb/III dossier requirements, which materially reduces the original clinical work needed and, per consultancy experience, tends to reduce Requerimiento cycles. However, this operates within the standard review timeline — no currently-operative, officially confirmed fast-track legal pathway with a shorter statutory clock tied specifically to FDA/CE approval was independently verifiable against INVIMA sources this round (Element 8). China's NMPA carries no recognized weight in Colombian registration at all.

Is there an emergency or exception pathway for devices not yet registered in Colombia?

Yes — Decreto 4725/2005 Article 48 allows INVIMA to authorize import, without a prior Registro Sanitario, of a device that is essential and irreplaceable for preserving life or alleviating suffering and unavailable domestically in sufficient quantity. The applicant must provide a free-sale certificate from the country of origin's competent authority, legal-constitution documentation, and a product quality certificate, filed through VUCE. This is a genuine, codified exception mechanism, distinct from — and more narrowly scoped than — a general reference-market reliance pathway.

Is Colombia's medical device regulation about to change?

A draft decree would replace both Decreto 4725/2005 and Decreto 3770/2004 with a unified notificación/registro/permiso model aligned to IMDRF definitions, motivated by Colombia's September 2025 IMDRF affiliate-member status. As of this page's verification date, the draft has cleared its WTO public-comment deadline (17 July 2026) but has not been presidentially sanctioned or published, and it proposes an 18-month transition period after eventual publication. Decreto 4725/2005 and Decreto 3770/2004 remain the operative law today — treat the draft as a planning input, not current compliance guidance (Element 6).

Official Sources and Verification Dates

• INVIMA official portal: https://www.invima.gov.co (accessed 2026-08-17)
• SIRIS electronic filing system: https://siris.invima.gov.co (accessed 2026-08-17)
• Decreto 4725 de 2005 (official PDF): https://www.invima.gov.co/invima_website/static/attachments/normatividad_normatividad_interna/decreto_4725_2005_2.pdf; biblioteca summary: https://www.invima.gov.co/biblioteca/decreto-4725-2005-registros-sanitarios-dispositivos-medicos (accessed 2026-08-17)
• Decreto 3770 de 2004 (biblioteca summary): https://www.invima.gov.co/biblioteca/decreto-3770-2004-registros-sanitarios-reactivos-in-vitro; IVD hub: https://www.invima.gov.co/node/71 (accessed 2026-08-17)
• Decreto 582 de 2017 (official PDF): https://www.invima.gov.co/invima_website/static/attachments/dispositivos_dispositivos_medicos_equipos_biomedicos/decreto_0582_2017.pdf (accessed 2026-08-17)
• Resolución 4816 de 2008 — Programa Nacional de Tecnovigilancia (official PDF and biblioteca summary): https://www.invima.gov.co/invima_website/static/attachments/normatividad_normatividad_interna/resolucion_004816_20Noviembre_2027_20de_202008_1.pdf, https://www.invima.gov.co/biblioteca/resolucion-4816-2008-programa-nacional-tecnovigilancia (accessed 2026-08-17)
• Resolución 4002 de 2007 — Manual de Requisitos CCAA (biblioteca summary): https://www.invima.gov.co/biblioteca/resolucion-4002-2007-manual-requisitos-almacenamiento-dispositivos-medicos (accessed 2026-08-17)
• Resolución 1405 de 2022 — estándar semántico / UDI-DI: https://www.invima.gov.co/productos-vigilados/dispositivos-medicos/estandar-semantico-codificacion-dispositivos (fetched and confirmed 2026-08-17)
• INVIMA tarifas hub: https://www.invima.gov.co/tramites-y-servicios/tarifas (fetched 2026-08-17; itemized 2026 Manual Tarifario figures for Clase I/IIa, modifications, and controlled-technology permit cross-checked via secondary summary — see 待核验 notes in Element 5)
• Automatic renewal — Circular Externa 100-0361-16 (biblioteca): https://www.invima.gov.co/biblioteca/circular-100-0361-16-renovaciones-registros-sanitarios-clase-i-iia; INVIMA news item: https://www.invima.gov.co/en/renovaciones-de-registros-sanitarios-para-dispositivos-medicos-clase-1-y-2a-seran-de-manera-automatica (accessed 2026-08-17, title/existence confirmed via search index; full page content sourced via search summary this round)
• Dispositivos médicos vitales no disponibles (Art. 48 special import authorization): https://www.invima.gov.co/productos-vigilados/dispositivos-medicos/dispositivos-medicos-vitales-no-disponibles (fetched and confirmed 2026-08-17)
• VUCE visto bueno guidance: https://www.invima.gov.co/biblioteca/guia-diligenciamiento-visto-bueno-vuce-invima-2024-v6 (accessed 2026-08-17)
• Pending unified decree — secondary reporting cross-checked across three independent outlets: https://www.lafm.com.co/sociedad/gobierno-expide-nuevo-regimen-sanitario-para-dispositivos-medicos-en-colombia-386894, https://www.infobae.com/colombia/2026/01/02/gobierno-expidio-nuevo-regimen-sanitario-para-dispositivos-medicos-en-colombia-estos-son-los-puntos-clave-del-borrador-de-decreto/, https://consultorsalud.com/regimen-unico-dispositivos-medicos-impactos/; draft text: https://www.minsalud.gov.co/Normatividad_Nuevo/PD%20Regimen%20Sanitario%20DM.pdf (accessed 2026-08-17)
• IMDRF affiliate membership and Pacific Alliance cooperation — secondary summary: https://paginaweb.invima.gov.co/autoridades-sanitarias-de-la-alianza-del-pacífico-firman-compromiso-para-agilizar-el-registro-de-medicamentos.html (accessed 2026-08-17)
• USD/COP reference exchange rate (2026-08-16, ~3,128.65): https://www.xe.com/en-us/currencyconverter/convert/?Amount=1&From=USD&To=COP (accessed 2026-08-17)
• Representative channel/procurement sources: https://www.contratos.gov.co (SECOP), https://www.adres.gov.co
• Verification date: 2026-08-17

Items flagged for further verification (【待核验】)

• The exact 2026 Manual Tarifario fee for Clase IIb and Clase III initial Registro Sanitario applications — this round confirmed the Clase I/IIa figure (COP 3,898,330) and modification fees directly, but could not extract the IIb/III line items from the official PDF; the previously cited COP 6,000,000–15,000,000 range should be treated as a planning floor pending direct confirmation.
• Whether the renewal fee is genuinely 60–80% of the initial application fee — sourced this round only from secondary consultancy summaries, not the official Manual Tarifario.
• The complete, class-by-class transitional timetable for UDI-DI compliance under Resolución 1405/2022 Article 15 — this round confirmed the 8 February 2024 threshold date for new registrations but not the full staged schedule for pre-existing registrations by class.
• Whether Tecnovigilancia under Resolución 4816/2008 still requires a distinct 30-day "final report" following the 72-hour immediate report — this round independently confirmed only the 72-hour immediate-report requirement.
• Whether INVIMA has published any software/SaMD-specific technical circular supplementing Decreto 4725/2005 Articles 6–7 — none was found this round, but a narrow supplementary circular not indexed in this round's search cannot be ruled out.
• Whether a formally named, currently-operative "Registro Sanitario Simplificado" fast-track legal pathway for CE/FDA-backed Clase IIb/III devices exists with an official compressed timeline (as distinct from the confirmed practice of accepting CE/FDA data as supporting evidence within the standard timeline) — this round could not confirm such a distinct named pathway against an official INVIMA legal source.